Lack of effect of methotrexate on the expression of constitutive hepatic cytochromes P450 in the male rat

Xenobiotica

Volumn 26, Issue 5, 1996, Pages 503-514

  Cheung, R L H ^a   Lee, C ^a   Jones, E J ^a   Riddick, D S ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRINE N DEMETHYLASE; ANDROSTENEDIONE; CYTOCHROME P450 ISOENZYME; MESSENGER RNA; METHOTREXATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; STEROID MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME; LIVER WEIGHT; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; STEROID HYDROXYLATION;

ANIMALIA;

EID: 0029891878     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046728     Document Type: Article

References (53)

1. AARBAKKE, J., and SLORDAL, L., 1994, Effects of anticancer drugs on drug metabolism. In Anticancer Drugs : Reactive Metabolism and Drug Interactions (International Encyclopedia of Pharmacology and Therapeutics, Section 141), edited by G. Powis (Oxford: Pergamon), pp. 427-438.
2. BALIS, F. M., 1986, Pharmacokinetic drug interactions of commonly used anticancer drugs. Clinical Pharmacokinetics, 11, 223-235.
3. BASU, T. K., and WILLIAMS, D. C., 1975, Effects of methotrexate and phenobarbital on the hepatic microsomal drug-metabolizing enzymes in normal rat. Chemotherapy, 21, 33-40.
4. BLACK, S. D., and COON, M. J., 1987, P-450 cytochromes: structure and function. Advances in Enzymology, 60, 35-87.
5. CHANG, T. K. H., WEBER, G. F., CRESPI, C. L., and WAXMAN, D. J., 1993, Differential activation of cyclophosphamide and ifosphamide by cytochrome-P-450-2B and cytochrome-P450-3A in human liver microsomes. Cancer Research, 53, 5629-5637.
6. CHOMCZYNSKI, P., and SACCHI, N., 1987, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry, 162, 156-159.
7. CLARKE, L., and WAXMAN, D. J., 1989, Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Research, 49, 2344-2350.
8. COOPER, K. O., REIK, L. M., JAYYOSI, Z., BANDIERA, S., KELLEY, M., RYAN, D. E., DANIEL, R., MCCLUSKEY, S. A., LEVIN, W., and THOMAS, P. E., 1993, Regulation of 2 members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Archives of Biochemistry and Biophysics, 301, 345-354.
9. CORREIA, M. A., 1995, Rat and human liver cytochromes P450. Substrate and inhibitor specificities and functional markers. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd edn, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 607-630.
10. DE BRUIJN, E. A., DRIESSEN, O., LEEFLANG, P., VAN DEN BOSCH, N., VAN STRIJEN, E., SLEE, P. H. T. J., and HERMANS, J., 1986, Pharmacokinetic interactions of cyclophosphamide and 5-fluorouracil with methotrexate in an animal model. Cancer Treatment Reports, 70, 1159-1165.
11. DONELLI, M. G., FRANCHI, G., and ROSSO, R., 1970, The effect of cytotoxic agents on drug metabolism. European Journal of Cancer, 6, 125-126.
12. DONELLI, M. G., and GARATTINI, S., 1971, Drug metabolism after repeated treatments with cytotoxic agents. European Journal of Cancer, 7, 361-364.
13. DRAGO, J. R., and NESBITT, J. A., 1986, The Nb transitional cell bladder carcinoma model: dose response to methotrexate and adriamycin. Anticancer Research, 6, 1019-1020.
14. EL DAREER, S. M., TILLERY, K. F., and HILL, D. L., 1981, Disposition of 5-methyltetrahydrohomofolate and methotrexate in rats. Cancer Treatment Reports, 65, 101-106.
15. GONZALEZ, F. J., SONG, B.-J., and HARDWICK, J. P., 1986, Pregnenolone 16α-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation. Molecular and Cellular Biology, 6, 2969-2976.
16. GRAHAM, M. A., RILEY, R. J., and KERR, D. J., 1991, Drug metabolism in carcinogenesis and cancer chemotherapy. Pharmacology and Therapeutics, 51, 275-289.
17. GUENGERICH, F. P., 1988, Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Research, 48, 2946-2954.
18. GUENGERICH, F. P., 1991, Reactions and significance of cytochrome P-450 enzymes. Journal of Biological Chemistry, 266, 10019-10022.
19. GUENGERICH, F. P., DANNAN, G. A., WRIGHT, S. T., MARTIN, M. V., and KAMINSKY, K. S., 1982, Purification and characterization of liver microsomal cytochromes P-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or β-naphthoflavone. Biochemistry, 21, 6019-6030.
20. GUITTON, J., SOUILLET, G., RIVIERE, J. L., GERARD, F., GUILLUY, R., and BRAZIER, J. L., 1994, Action of methotrexate on cytochrome P-450 monooxygenases in rats. Study performed with [C-13]-aminopyrine micro breath test. European Journal of Drug Metabolism and Pharmacokinetics, 19, 119-124.
21. IMAOKA, S., INOUE, K., and FUNAE, Y., 1988, Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Archives of Biochemistry and Biophysics, 265, 159-170.
22. IRELAND, C. M., and PITTMAN, S. M., 1995, Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs. Biochemical Pharmacology, 49, 1491-1499.
23. KIRITA, S., and MATSUBARA, T., 1993, cDNA cloning and characterization of a novel member of steroid- induced cytochrome-P450 3A in rats. Archives of Biochemistry and Biophysics, 307, 253-258.
24. KOMINAMI, S., 1993, Substrate binding and the reduction of cytochrome P-450. In Cytochrome P-450, 2nd edn, edited by T. Omura, Y. Ishimura, and Y. Fujii-Kuriyama (Tokyo: Kodansha/ Weinheim: VCH), pp. 64-80.
25. KOMORI, M., and ODA, Y., 1994, A major glucocorticoid-inducible P450 in rat liver is not P450 3A1. Journal of Biochemistry, 116, 114-120.
26. KROES, A. C. M., LINDEMANS, J., SCHOESTER, M., and ABELS, J., 1986, Enhanced therapeutic effect of methotrexate in experimental rat leukemia after inactivation of cobalamin (vitamin B12) by nitrous oxide. Cancer Chemotherapy and Pharmacology, 17, 114-120.
27. LEBLANC, G. A., SUNDSETH, S. S., WEBER, G. F., and WAXMAN, D. J., 1992, Platinum anticancer drugs modulate P-450 messenger RNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Research, 52, 540-547.
28. LEBLANC, G. A., and WAXMAN, D. J., 1988, Feminization of rat hepatic P-450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes. Journal of Biological Chemistry, 263, 15732-15739.
29. LEBLANC, G. A., and WAXMAN, D. J., 1989, Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metabolism Reviews, 20, 395-439.
30. LEBLANC, G. A., and WAXMAN, D. J., 1990, Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Research, 50, 5720-5726.
31. LOADMAN, P. M., and BIBBY, M. C., 1994, Pharmacokinetic drug interactions with anticancer drugs. Clinical Pharmacokinetics, 26, 486-500.
32. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L., and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
33. MAZEL, P., 1971, Experiments illustrating drug metabolism in vitro. In Fundamentals of Drug Metabolism and Drug Disposition, edited by B. N. LaDu, H. G. Mandel, and E. L. Way (Baltimore: Williams & Wilkins), pp. 546-560.
34. MCCLUSKEY, S. A., RACZ, W. J., and MARKS, G. S., 1986, Properties of 17- to 19-day-old chick embryo liver microsomes: induction of cytochrome P-450, effect of storage at low temperature, and resistance to lipid peroxidation. Journal of Pharmacological Methods, 16, 111-123.
35. NASH, T., 1953, The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochemical Journal, 55, 416-421.
36. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K., and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12, 1-51.
37. OMURA, T., and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
38. PRATT, W. B., RUDDON, R. W., ENSMINGER, W. D., and MAYBAUM, J., 1994, The Anticancer Drugs, 2nd edn (New York: Oxford University Press).
39. RAM, P. A., and WAXMAN, D. J., 1991, Hepatic P450 expression in hypothyroid rats: differential responsiveness of male-specific P450 form-2a (IIIA2), form-2c (IIC11), and RLM2 (IIA2) to thyroid hormone. Molecular Endocrinology, 5, 13-20.
40. RYAN, D. E., and LEVIN, W., 1990, Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacology and Therapeutics, 45, 153-239.
41. RYAN, D. E., and LEVIN, W., 1993, Age- and gender-related expression of rat liver cytochrome P450. In Cytochrome P450 (Handbook of Experimental Pharmacology, vol. 105), edited by J. B. Schenkman and H. Greim (Berlin: Springer), pp. 461-476.
42. SCHEUFLER, E., ZETLER, G., and IVEN, H., 1981, Pharmacokinetics and organ distribution of methotrexate in the rat. Pharmacology, 23, 75-81.
43. STROBEL, H. W., and DIGNAM, J. D., 1978, Purification and properties of NADPH-cytochrome P-450 reductase. Methods in Enzymology, 52, 89-96.
44. STUPANS, I., RICHARDS, D. A., and MCCLURE, M. T., 1995, Effects of 5-fluorouracil treatment on rat liver microsomal enzymes. Xenobiotica, 25, 1-8.
45. TARNOWSKI, G. S., SCHMID, F. A., CAPPUCCINO, J. G., and STOCK, C. C., 1966, Chemotherapy studies in an animal tumor spectrum. II. Sensitivity of tumors to fourteen antitumor chemicals. Cancer Research, 26, 181-206.
46. WAXMAN, D. J., 1984, Rat hepatic cytochrome P-450 isozyme 2c. Identification as a male-specific, developmentally induced steroid 16α-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. Journal of Biological Chemistry, 259, 15481-15490.
47. WAXMAN, D. J., 1988, Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression. Biochemical Pharmacology, 37, 71-84.
48. WAXMAN, D. J., 1991, Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods in Enzymologv, 206, 249-267.
49. WAXMAN, D. J., DANNAN, G. A., and GUENGERICH, F. P., 1985, Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry, 24, 4409-4417.
50. WAXMAN, D. J., KO, A., and WALSH, C., 1983, Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. Journal of Biological Chemistry, 258, 11937-11947.
51. WEBER, G. F., and WAXMAN, D. J., 1993, Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochemical Pharmacology, 45, 1685-1694.
52. C19 steroids by five highly purified and reconstituted rat hepatic cytochrome P-450 isozymes. Journal of Biological Chemistry, 258, 8839-8847.
53. ZHOU, X.-J., ZHOU-PAN, X.-R., GAUTHIER, T., PLACIDI, M., MAUREL, P., and RAHMANI, R., 1993, Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation: metabolic drug interactions. Biochemical Pharmacology, 45, 853-861.